The biopharmaceutical company, Icagen, focuses on discovering and developing novel orally-administered small molecule drugs that modulate ion channel targets. Their current pipeline includes ICA-105665 for epilepsy and neuropathic pain, and Senicapoc for the treatment of asthma. In addition, Icagen offers target-based drug discovery services for pharmaceutical and biotechnology companies, with a focus on ion channels, kinases, GPCR's, and transporters. The company collaborates with global partners to generate high-quality, advanced leads in multi-year, integrated drug discovery programs. With over 20 years of experience in early discovery, Icagen's team of scientists uses state-of-the-art computational chemistry methods to determine target feasibility and combines virtual screening, ultra-high throughput screening, biology, and medicinal chemistry to generate viable leads.